Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview

Relmada Therapeutics

04/08/2026 23:10

Relmada Therapeutics Inc RLMD.OQ RLMD.O is expected to  show no change in quarterly revenue when it reports  results on August 6 for the period ending June 30 2026

​LSEG's mean analyst estimate for Relmada Therapeutics Inc is for a loss of 20 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Relmada Therapeutics Inc is $12.00, about 119.4% above its last closing price of $5.47
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.20
-0.19
-0.22
Missed
-12.8
Dec. 31 2026
-0.14
-0.14
-0.29
Missed
-107.1
-0.30
​
-0.30
​​Mar. 31 2025
-0.31
-0.58
Missed
-87.1
Dec. 31 2024
-0.66
-0.70
-0.62
Beat
11.2​
Sep. 30 2024
-0.64
-0.64
-0.72
Missed
-12.3
Jun. 30 2024
-0.81
-0.83
-0.59
Beat
28.6
This summary was machine generated August 4 at 22:10 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)